VITAL KSK HOLDINGS,INC. Q4 FY2025 earnings call

2025 Fiscal Year Full Year Results

• All top- and bottom-line metrics achieved year-over-year growth; every metric exceeded 100% of initial guidance. Total consolidated revenue was 600.37 billion yen (102.2% YoY), operating profit 5.706 billion yen (102.7% YoY), ordinary profit 6.97 billion yen (106.3% YoY), net income attributable to parent shareholders 7.308 billion yen (125.1% YoY), and ROE reached a post-2016 high of 6.9%.
• 4.238 billion yen in special gains were recorded from accelerated sales of cross-held policy stocks.

Mid-Term Management Plan 2027 (3-year plan ending March 2028) Strategic Priorities

• 1. Business Portfolio Management
  • All existing segments are evaluated annually based on ROIC and CAGR against a 6.0% hurdle rate (3-year average WACC). Low-return, unprofitable businesses will undergo restructuring or exit to reallocate capital to higher-growth opportunities.
  • Strengthen profitability of core pharmaceutical wholesale, consolidate/restructure low-return businesses, and invest in high-ROIC care rental business. Focus on new growth: expand 3PL logistics contracting and enter the unapproved drug import support pharmaceutical business.
  • Core Pharmaceutical Wholesale Strategy: Continue focus on high-margin new priority drugs, implement segment-specific pricing negotiation, pursue digital transformation (electronic delivery receipts are expected to reduce branch staff workload by ~23%) to improve productivity, expand specialist talent for high-value oncology drugs, build area-specific optimal distribution networks, and add value-added healthcare services. Target 620 billion yen in revenue and 7 billion yen in operating profit by FY2027.
  • Other Existing Business Strategies: Consolidate 6 pharmacy companies into 1 to improve productivity; pursue synergies from the recent Arrow Medical acquisition in animal health; focus capital on high-return care rental, restructure/exit low-margin business lines.
• 2. New Business Development
  • Logistics Contracting (3PL): Spin off the existing logistics business from pharmaceutical wholesale, open a new 3PL center in Isehara (Kanagawa) in 2026, pursue M&A of logistics firms to scale as a new profit pillar.
  • Pharmaceutical (Unapproved Drug Introduction Support): Lead collaboration with partners to bring Western-approved, Japan-unapproved new drugs to domestic market. This is a 3-year R&D phase that will increase SG&A in the near term, but will generate synergy with wholesale and 3PL businesses and add substantial long-term profit after launch. The investment committee ran extensive simulations, and even the worst-case scenario IRR exceeds the company's hurdle rate; the Board of Directors approved entry, with partners already lined up for clinical development and manufacturing.
• 3. Financial Strategy and Capital Policy
  • Target 35% equity ratio (2.9x financial leverage) and total asset turnover above 2.0. Accelerate disposal of cross-held policy stocks, bringing forward the target of reducing holdings to <10% of net asset value to 2029 (2 years ahead of original schedule), with an interim target of <20% by 2027.
  • Update shareholder return policy: Increase target DOE (dividend on equity) from 2.0% or higher to 3.0% or higher, replace the previous 50%+ total payout policy with flexible return: any excess cash after growth investment will be used for additional shareholder returns. Over the 3-year plan, total 9.4 billion yen will be allocated to dividends, targeting ~68 yen annual dividend per share with a 40-45% payout ratio.
  • Total expected cash inflow of 35.5 billion yen over 3 years: 9 billion yen for existing facility upgrades, 11 billion yen for growth investment (new business and M&A), 2.6 billion yen for debt repayment, 9.4 billion yen for dividends, 3.5 billion yen retained for future growth.
• 4. Governance and Group Management Enhancement
  • Strengthen board independence and diversity; add CFO and CHRO roles to clarify responsibility. Formalize annual business evaluation and investment decision processes to ensure disciplined capital allocation.
  • Advance ESG initiatives: target 30% GHG emission reduction by 2030 vs 2020, strengthen human capital management and next-generation leadership development, enhance internal compliance and IR activities.

1. Pharmaceutical Wholesale Segment: Revenue of 564.614 billion yen (102.1% YoY), accounting for 94.0% of total consolidated revenue. Operating profit of 5.163 billion yen (105.1% YoY), with real operating profit (excluding one-time prior year COVID-19 vaccine delivery gains) of 5.353 billion yen (151% YoY). Growth was driven by increased sales of new drug priority-priced products (+1.33 billion yen), originator drugs (+1.52 billion yen), generics (+0.58 billion yen), and vaccines (+0.99 billion yen), offsetting a 2.52 billion yen sales decline in long-listed products due to drug price revisions and 0.47 billion yen decline in COVID-19 therapeutic sales.
2. Pharmacy Segment: Revenue of 19.552 billion yen (102.3% YoY), accounting for 3.3% of total consolidated revenue. Operating profit of 0.251 billion yen (81.0% YoY), with declining profitability driven by drug price revision impacts.
3. Animal Health Pharmaceutical Wholesale Segment: Revenue of 11.626 billion yen (105.4% YoY), accounting for 1.9% of total consolidated revenue. Operating profit of 0.314 billion yen (89.6% YoY), with profitability pressure from rising purchase prices, partially offset by the 2024 acquisition of Arrow Medical Co., Ltd.
4. Other Business (renamed to Care Rental and Other Business): Revenue of 4.577 billion yen (102.4% YoY), accounting for 0.8% of total consolidated revenue. Operating loss narrowed by 30 million yen to 0.078 billion yen, with overall profitability improvement across segments.

• FY2026 (ending March 2026) Full Year Guidance: Target consolidated revenue of 620 billion yen, core operating profit (excluding pharmaceutical business R&D expense) of 6 billion yen, adjusted ROE (excluding pharmaceutical business R&D impact) of 7.6%.
• Mid-Term Management Plan 2027 (ending March 2028) Targets: Total consolidated revenue of 660 billion yen (110% of FY2024 level), core operating margin (excluding pharmaceutical R&D) of 1.15% or higher, adjusted ROE (excluding pharmaceutical R&D) of 8.0% or higher.
• Pharmaceutical Wholesale Segment FY2027 Target: 620 billion yen revenue (110% of FY2024 level), 7 billion yen operating profit (140% of FY2024 level), 1.13% operating margin.
• Dividend Guidance: Annual dividend for FY2026 is set at 68 yen per share, a 23 yen year-over-year increase and a new all-time high. Interim earnings guidance is discontinued starting this fiscal year due to uncertain timing of pharmaceutical business R&D expense recognition, with only full-year guidance disclosed.

• The new pharmaceutical unapproved drug introduction business carries inherent risks: failure to obtain domestic marketing approval, failure to secure an expected drug price that meets profitability projections, and higher-than-expected operating and development costs. Management notes the risk of non-approval is very low given the drugs are already Western-approved, and risk is controlled via pre-investment scenario simulations and collaboration with experienced partner firms to share costs and responsibility.
• Ongoing annual drug price revisions in Japan create structural downward pressure on pharmaceutical wholesale sales and profitability across all core segments.
• Persistent demographic decline and shrinking working-age population increases labor costs and operational pressure for the distribution-focused business.
• Low capital efficiency from historical cross-held policy stock holdings has weighed on ROE and PBR, though disposal is being accelerated to address this.

The provided transcript does not include a transcribed question and answer session portion from the earning call.